2020 In Review: Highlights, Lowlights and Forgotten Milestones
Executive Summary
Our interactive timeline tracks the rush of activities that led to the authorization of the first coronavirus vaccines and includes other major non-COVID developments that provide a full picture of this extraordinary year.
You may also be interested in...
Drug Rejection Hearings Are Having A Moment At US FDA
With Intarcia's request, the rarely used mechanism could now produce two hearing this year, but outcomes of the few other times the process has been undertaken should not generate a lot of confidence for sponsors that this a path that they want to go down.
Improper Dose In Phase II Trials Can ‘Make Or Break’ Drug Program, FDA’s Stein Says
Director of the US FDA’s Office of New Drugs says there will be a greater focus on identifying the optimal dose before a drug candidate advances into Phase III trials, but the problem is not limited to oncology, the target of Project Optimus.
Some US FDA Advisory Committee Meetings Likely To Remain Virtual Post-Pandemic
Peter Stein says FDA will set criteria for holding a virtual meeting and will be seeking stakeholder feedback.